Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.41 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031194 | 1.00 | LPAR1 (0.50) | LPAR1LPAR3NPSR1MAPTLPAR2 | |
| SCHEMBL4034577 | 0.89 | LPAR1 (0.52) | LPAR1LPAR3NPSR1MAPTLPAR2 | |
| SCHEMBL4030336 | 0.87 | MAPT (0.51) | LPAR1LPAR3NPSR1MAPTLPAR2 | |
| SCHEMBL4029085 | 0.87 | LPAR1 (0.58) | LPAR1LPAR3NPSR1MAPTLPAR2 | |
| SCHEMBL4028917 | 0.87 | LPAR1 (0.58) | LPAR1LPAR3NPSR1MAPTLPAR2 | |
| SCHEMBL4028365 | 0.85 | LPAR1 (0.67) | LPAR1LPAR3NPSR1MAPTTP53 | |
| SCHEMBL4031106 | 0.85 | LPAR1 (0.67) | LPAR1LPAR3NPSR1MAPTTP53 | |
| SCHEMBL4032557 | 0.85 | LPAR1 (0.67) | LPAR1LPAR3NPSR1MAPTTP53 | |
| SCHEMBL11977991 | 0.84 | MAPT (0.44) | LPAR1LPAR3NPSR1MAPTLPAR2 | |
| SCHEMBL11979371 | 0.84 | LPAR1 (0.55) | LPAR1LPAR3NPSR1MAPTLPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1258484-B1 | NOVEL ISOXAZOLE AND THIAZOLE COMPOUNDS AND USE THEREOF AS DRUGS | KYOWA HAKKO KIRIN CO LTD (JP) | 2009-01-14 | — | — | EP | claimed |
| US-6964975-B2 | Isoxazole and thiazole compounds and use thereof as medicine | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-11-15 | — | — | US | claimed |
| EP-1258484-B1 | NOVEL ISOXAZOLE AND THIAZOLE COMPOUNDS AND USE THEREOF AS DRUGS | KYOWA HAKKO KIRIN CO LTD (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-6964975-B2 | Isoxazole and thiazole compounds and use thereof as medicine | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-11-15 | — | — | US | disclosed |
| US-20030114505-A1 | Novel isoxazole and thiazole compounds and use thereof as drugs | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1258484-A1 | NOVEL ISOXAZOLE AND THIAZOLE COMPOUNDS AND USE THEREOF AS DRUGS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114505-A1 | Novel isoxazole and thiazole compounds and use thereof as drugs | LPAR3, LPAR1, LPAR4 | LPAR1 2/4885LPAR3 1/4885NPSR1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.